Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
British Journal of Haematology
|
May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
Nicole A Carreau, Philippe Armand, Reid W Merryman, et al.
Blood Advances
|
August 18, 2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
Jackson T Bowers, Jacob Anna, Steven M Bair, et al.
American Journal of Hematology
|
January 11, 2023
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma
Sanjal H Desai, Michael A Spinner, Kevin David, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The Oncologist
|
July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
Nicole A Carreau, Orrin Pail, Philippe Armand, et al.
Blood
|
November 15, 2013
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Michael A Spinner, Lauren A Sanchez, Amy P Hsu, et al.
Blood Cancer Journal
|
June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
Sanjal H Desai, Susan M Geyer, Levi Pederson, et al.
The Oncologist
|
April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma
Reid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
Blood Advances
|
September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Sanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Blood Advances
|
March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
British Journal of Haematology
|
May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
Nicole A Carreau, Philippe Armand, Reid W Merryman, et al.
Blood Advances
|
August 18, 2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
Jackson T Bowers, Jacob Anna, Steven M Bair, et al.
American Journal of Hematology
|
January 11, 2023
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma
Sanjal H Desai, Michael A Spinner, Kevin David, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The Oncologist
|
July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
Nicole A Carreau, Orrin Pail, Philippe Armand, et al.
Blood
|
November 15, 2013
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Michael A Spinner, Lauren A Sanchez, Amy P Hsu, et al.
Blood Cancer Journal
|
June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
Sanjal H Desai, Susan M Geyer, Levi Pederson, et al.
The Oncologist
|
April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma
Reid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
Blood Advances
|
September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Sanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Blood Advances
|
March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Page
of 5